Fusion Antibodies plc (AIM: FAB), the Belfast-based contract research organisation specialising in pre-clinical antibody discovery, engineering and supply, has announced a new affinity engineering contract with a returning European-listed global pharmaceutical company. The project will use the company's proprietary Rational Affinity Maturation Programme technology, known as RAMP, to engineer the client's lead antibody. The contract is expected to generate revenues in excess of £45,000 and is due to be completed within the current financial year, contributing to near-term revenues for the AIM-listed firm.

Key Points

  • Fusion Antibodies plc (AIM: FAB) is a Belfast-based specialist contract research organisation focused on antibody engineering for therapeutic and diagnostic applications
  • The company has been awarded a new RAMP affinity engineering project by a returning European-listed global pharmaceutical client under an existing master services agreement
  • The RAMP Project is expected to generate revenues in excess of £45,000, with completion anticipated within the current financial year
  • Investors may be watching for further contract wins and repeat business as Fusion seeks to deepen commercial relationships with major pharmaceutical companies

Fusion Antibodies Applies Proprietary RAMP Technology to Returning Client's Lead Antibody

The newly awarded project requires Fusion Antibodies to perform affinity engineering on the client's lead antibody, deploying the company's proprietary RAMP technology. The announcement states the contract has been awarded under an existing master services agreement, indicating an established commercial framework between the two parties. Fusion has previously undertaken similar affinity engineering work for this client, and the renewed engagement underscores the technical relevance of the RAMP platform. The company is also seeking to commercialise additional technologies, including OptiMAL® and microfluidic cell line development, as part of its broader growth strategy.

Contract Expected to Contribute Over £45,000 in Revenue During Current Financial Year

The RAMP Project is expected to generate revenues in excess of £45,000, with all work anticipated to be completed within Fusion's current financial year. The announcement confirms the project will contribute to the company's revenues during this period. While the contract value is modest relative to the company's overall revenue base, the award is consistent with Fusion's stated strategy of building resilience through recurring business with established pharmaceutical partners, rather than relying solely on new client acquisition. The company did not disclose further financial guidance or the precise completion date in the announcement.

Repeat Business from Blue-Chip Pharma Client Supports Fusion's Revenue Resilience Strategy

Fusion Antibodies describes its client base as international and blue-chip, stating it has worked with eight of the top ten global pharmaceutical companies by revenue. The re-engagement with this European-listed global pharmaceutical company reflects Fusion's objective of converting one-off engagements into longer-term relationships. Having successfully sequenced and expressed over 400 antibodies and completed over 295 humanisation projects since 2012, the company positions its specialist capabilities as a key commercial differentiator. The Belfast-based CRO was originally established in 2001 as a spin-out from Queen's University Belfast and was admitted to AIM in December 2017.